Risk Factors for Hearing Loss in Patients with Cystic Fibrosis

Tarshish, Yael; Huang, Lin; Jackson, Frank I.; Edwards, Julianne; Fligor, Brian J.; Wilkins, Abigail; Uluer, Ahmet; Sawicki, Gregory S.; Kenna, Margaret A.

doi:10.3766/jaaa.14104

Cited by 9 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This group further reported that 74% of these ears with SNHL had hearing loss in the frequency range ≥9.0 kHz (14). A retrospective study by Tarshish (12), reported on the risk factors and prevalence of SNHL in a large cohort of CF patients (mean age= 18 yr., SD = 10 yr.) who had received audiometric evaluations between 2007 and 2010. They found that 21% (37 of 178) had SNHL in at least one ear.…”

Section: Discussionmentioning

confidence: 99%

“…They found that 21% (37 of 178) had SNHL in at least one ear. However, of these ears 94.1% had unilateral SNHL, and 77.8% had bilateral SNHL at their highest test frequencies (6.0–8.0 kHz) (12). When we age matched our study (re: mean age of 26 yr., SD ±10) to Tarshish’s cohort, patients with CF between 20 to 49 years old, we found a prevalence for SNHL of ~42% within the conventional frequency range, all those had SNHL in the 6.0–8.0 kHz range, reflecting the normal progression of ototoxic damage.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Garinis

Cross

Srikanth

et al. 2017

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Background Aminoglycosides (AGs) and glycopeptides are antibiotics essential for treating life-threatening respiratory infections in patients with cystic fibrosis (CF). The goal of this study was to examine the effects of cumulative intravenous AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status. Methods Hearing thresholds were measured from 0.25 to 16.0 kHz, in 81 participants with CF. Participants were categorized into two groups: normal hearing in both ears (≤25 dB HL for all frequency bands) or hearing loss (>25 dB HL for any frequency band in either ear). Participants were also characterized by their cumulative intravenous (IV)-AG (with or without vancomycin) exposure by comparing the total number of lifetime cumulative IV doses to a method that additionally accounts for the total number of doses per day (weighted method) per course of treatment. Results Participants in the hearing loss group were significantly older than those in the normal-hearing group. After adjusting for gender and age at the time of hearing test, participants in the two highest-quartile exposure groups were more likely to have permanent sensorineural hearing loss than those in the two lowest-quartile exposure groups. Conclusions Cumulative IV antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects. A trend for increasing odds of hearing loss was associated with increasing cumulative IV-antibiotic dosing.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Garinis

Cross

Srikanth

et al. 2017

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…Although we tend to focus on the proposition that patient response is attributable to some exacerbation management approaches that are superior to others, it may be as important to recognize practices that offer little or no difference in treatment response while significantly reducing treatment burden, resource utilization, and/or potential for patient toxicity. [31] Without prospective protocol-based comparative studies of different treatment regimens using efficacy measures considered both valid and compelling to CF patients, families, and care-providers, it will be difficult to optimize exacerbation treatment paradigms.…”

Section: Discussionmentioning

confidence: 99%

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis

VanDevanter

Heltshe

Spahr

et al. 2017

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“… 31 , 33 , 54 The total cumulative number of IV courses of aminoglycosides (>10) and the total cumulative aminoglycoside dose induce a higher risk of ototoxicity. 35 , 40 , 76 , 77 In addition to conductive, sensorineural and mixed hearing loss, substantially higher rates of multiple symptoms associated with audiological disorders (such as tinnitus, imbalance and dizziness) have been reported in cystic fibrosis children compared with healthy controls. 54 Based on these findings, we suggest that routine hearing screening may be considered during and after aminoglycoside exposure.…”

Section: Discussionmentioning

confidence: 99%

Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review

Diepstraten

Hoetink

Grotel

et al. 2021

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

Background Ototoxicity has been reported after administration of aminoglycosides and glycopeptides. Objectives To identify available evidence for the occurrence and determinants of aminoglycoside- and glycopeptide-related ototoxicity in children. Materials and methods Systematic electronic literature searches that combined ototoxicity (hearing loss, tinnitus and/or vertigo) with intravenous aminoglycoside and/or glycopeptide administration in children were performed in PubMed, EMBASE and Cochrane Library databases. Studies with sample sizes of ≥50 children were included. The QUIPS tool and Cochrane criteria were used to assess the quality and risk of bias of included studies. Results Twenty-nine aminoglycoside-ototoxicity studies met the selection criteria (including 7 randomized controlled trials). Overall study quality was medium/low. The frequency of hearing loss within these studies ranged from 0%–57%, whereas the frequency of tinnitus and vertigo ranged between 0%–53% and 0%–79%, respectively. Two studies met the criteria on glycopeptide-induced ototoxicity and reported hearing loss frequencies of 54% and 55%. Hearing loss frequencies were higher in gentamicin-treated children compared to those treated with other aminoglycosides. In available studies aminoglycosides had most often been administered concomitantly with platinum agents, diuretics and other co-medication. Conclusions In children the reported occurrence of aminoglycoside/glycopeptide ototoxicity highly varies and seems to depend on the diagnosis, aminoglycoside subtype and use of co-administered medication. More research is needed to investigate the prevalence and determinants of aminoglycoside/glycopeptide ototoxicity. Our results indicate that age-dependent audiological examination may be considered for children frequently treated with aminoglycosides/glycopeptides especially if combined with other ototoxic medication.

show abstract

Risk Factors for Hearing Loss in Patients with Cystic Fibrosis

Abstract: This study suggests that age and frequency of hospitalizations are key predictors of HL development. Increased awareness and regular screening for SNHL should be included in the routine care of CF patients, particularly those at the highest risk.

Cited by 9 publications

References 21 publications

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis

Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review

Contact Info

Product

Resources

About